Healthcare
Terumo Corporation(TRUMY)
Live Price
Offline$14.00
+0.29% today
1Y Change
-24.53%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $2.93T
- Revenue Growth
- +12.4%
- EPS Growth
- +10.5%
- Dividend Yield
- 1.5%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Terumo Corporation (TRUMY) is a Healthcare stock with a market cap of $2.93T and listed on OTC. The stock last traded around $14.00 and down 24.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +12.4%, EPS growth of +10.5%, a dividend yield of 1.5%. What stands out right now is revenue +12.4%, EPS +10.5%, free cash flow +90.1% with operating margin 17.2% and ROIC 7.1%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.9 and price/sales 2.7. Stock Foundry combines TRUMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.4% vs +7.6% peer median
Operating Margin
Below sector median
+17.2% vs +19.4% peer median
P/E
Below sector median
22.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +12.4% and EPS at +10.5%, with operating margin around 17.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | +13.4% | +18.2% | โ |
2026 Feb 13, 2026 | -3.6% | -14.3% | -13.7% | -9.8% |
2025 Nov 12, 2025 | -0.7% | -1.0% | -1.6% | -3.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRUMY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRUMY Max Drawdown
-35.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRUMY and SPY.
Company Overview
Terumo Corporation
Other OTC
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
- Leadership
- Hikaru Samejima
- IPO Date
- Jan 5, 2010
- Employees
- 30.2k
- Street Address
- 2-44-1, Hatagaya
- Mailing
- Tokyo, 151-0072
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3374 8111
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.9
- EV/EBITDA
- 11.6
- Price/Sales
- 2.7
- Price/Book
- 1.9
Growth
- Revenue
- +12.4%
- EPS
- +10.5%
- Free Cash Flow
- +90.1%
Profitability
- Gross Margin
- 53.3%
- Operating Margin
- 17.2%
- Net Margin
- 11.7%
- ROE
- 9.0%
- ROIC
- 7.1%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 1.51
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.